Project Grant R03AG087474
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $357K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $3,481,644 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mechanisms by which excessive amyloid-beta peptides impair brain lymphatic function and contribute to Alzheimer's disease and Down syndrome. The research program comprises three strategic aims. The first involves extensive molecular, cellular, structural, and functional analyses of brain lymphatics in mouse models of...
- The National Institute on Aging awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $889,728 on August 18, 2026, under the Aging Research program (CFDA 93.866) to develop circuit-based multi-focal neurostimulation targeting depression and memory in older adults with Alzheimer's dementia. The project combines transcranial direct current stimulation targeting the left prefrontal cortex to address depressive symptoms with transcranial alternating current stimulation...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Albany Medical College $451,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to identify endothelial gene targets over Alzheimer's disease progression. The research investigates alterations in brain endothelial translatome in Alzheimer's disease and vascular pathology across the progression timeline and in both sexes, addressing a gap in prior studies that were predominantly male or sex-unstratified. The project uses two Alzheimer's...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded Boston University Medical Campus $110,228 in project grant funding on February 7, 2027, to develop and validate a novel cellular model of entorhinal cortex layer II vulnerability in Alzheimer's disease under the Aging Research program (CFDA 93.866). The project will develop in vitro models using induced pluripotent stem cells (iPSCs) and direct fibroblast conversion to generate entorhinal cortex layer II (ECII)-like neurons for studying Alzheimer's disease...
- The National Institute on Aging awarded the Regenerative Research Foundation $428,175 on February 15, 2026, under the Aging Research program (CFDA 93.866) to develop a human induced pluripotent stem cell (iPSC)-derived three-dimensional vascular microphysiological model for studying cerebral amyloid angiopathy and Alzheimer's disease-related vascular pathology. The recipient will establish a 3D model incorporating microglia and vascular endothelial cells within a microfluidic device to enable...
- The National Institute of Neurological Disorders and Stroke awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $616,031 on May 5, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate arterial endothelial pannexin 1 channels in ischemic stroke-induced vascular dementia, with specific focus on age and sex differences. The research examines the role of cerebral endothelial pannexin 1 (PANX1)...
- The National Institute on Aging awarded the University of Massachusetts Medical School $419,946 on September 1, 2026, under the Aging Research program (CFDA 93.866) for research into RNA interference-mediated modulation of apolipoprotein E, innate immune response, and tau pathology as a disease-modifying treatment for Alzheimer's disease. The funded research develops and tests small interfering RNA scaffolds that simultaneously target multiple genes implicated in Alzheimer's disease progression....
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...